Rinciog, C.
Watkins, M.
Chang, S.
Maher, T. M.
LeReun, C.
Esser, D.
Diamantopoulos, A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
https://doi.org/10.1007/s40273-016-0480-2
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
https://doi.org/10.1136/bmjresp-2018-000397
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
Documents that mention this clinical trial
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
https://doi.org/10.1007/s40273-016-0480-2
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
https://doi.org/10.1136/bmjresp-2018-000397
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
Funding for this research was provided by:
Boehringer Ingelheim
Article History
First Online: 31 December 2016
Compliance with Ethical Standards
:
: This study was funded by Boehringer Ingelheim. Boehringer Ingelheim was involved in the analysis of clinical trial data.
: CR, SC and AD are employed by Symmetron Ltd, which received funding from Boehringer Ingelheim for this project. CLR received funding for this project from Symmetron Ltd. TMM has received consulting fees from Symmetron Ltd; industry-academic research funding from GlaxoSmithKline R&D, UCB and Novartis; and consultancy or speakers fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Dosa, Galapagos, GlaxoSmithKline R&D, ProMetic, Roche (and previously InterMune), Sanofi-Aventis, Takeda and UCB. TMM is supported by a National Institute for Health Research (NIHR) Clinician Scientist Fellowship (NIHR ref: CS-2013-13-017). DE is an employee of Boehringer Ingelheim. MW was an employee of Boehringer Ingelheim UK at the time this study was conducted. A copy of the cost-effectiveness model was provided to the journal for external review.